Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

54.10
-0.7600-1.39%
Post-market: 54.05-0.0495-0.09%19:58 EDT
Volume:1.50M
Turnover:81.98M
Market Cap:4.92B
PE:-9.94
High:55.59
Open:55.00
Low:54.00
Close:54.86
52wk High:71.13
52wk Low:30.04
Shares:90.95M
Float Shares:90.53M
Volume Ratio:0.79
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4437
EPS(LYR):-4.3416
ROE:-25.34%
ROA:-13.05%
PB:2.88
PE(LYR):-12.46

Loading ...

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

GlobeNewswire
·
Aug 29

Cathie Wood's Ark Raises Wager on Ethereum-Hoarding Bitmine, Dumps Sports Betting Giant DraftKings

Benzinga
·
Aug 28

CRISPR Therapeutics CEO Samarth Kulkarni Reports Disposal of Common Shares

Reuters
·
Aug 20

CureVac Reports Decrease in Net Financial Result for H1 2025; R&D Expenses Rise Amid Strategic Restructuring

Reuters
·
Aug 15

Truist Securities Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating

MT Newswires Live
·
Aug 09

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

GlobeNewswire
·
Aug 07

CRISPR Therapeutics Ag : Barclays Raises Target Price to $56 From $42

THOMSON REUTERS
·
Aug 06

Stock Track | CRISPR Therapeutics Soars 5.32% on Positive Analyst Ratings and ARK Investment's Large Purchase

Stock Track
·
Aug 06

Crispr Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 06

RBC Raises Price Target on CRISPR Therapeutics to $42 From $38, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Aug 05

BUZZ-Crispr Therapeutics falls after weak quarterly results

Reuters
·
Aug 05

Stock Track | CRISPR Therapeutics Plunges 8.86% Pre-Market on Q2 Revenue Miss and Widened Losses

Stock Track
·
Aug 05

Stock Track | CRISPR Therapeutics Plunges 8.46% as Q2 Revenue Misses Estimates, Net Loss Widens

Stock Track
·
Aug 05

CRISPR Therapeutics Ag : RBC Raises Target Price to $42 From $38

THOMSON REUTERS
·
Aug 05

CORRECTION: CRISPR Therapeutics Q2 Adj. EPS $(1.29) Beats $(1.47) Estimate, Sales $892.000K Miss $6.255M Estimate

Benzinga
·
Aug 05

CRISPR Therapeutics Q2 EPS $(2.40) Down From $(1.49) YoY

Benzinga
·
Aug 05

CRISPR Therapeutics Q2 revenue misses estimates, net loss widens

Reuters
·
Aug 05

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Hershey, Wingstop

Reuters
·
Jul 30

BUZZ-U.S. STOCKS ON THE MOVE-Visa, Kraft Heinz, Humana

Reuters
·
Jul 30